MDT

86.53

+0.49%↑

A

114.87

+1.31%↑

VEEV

173.27

-1.41%↓

HQY

81.97

+0.15%↑

CSBR

5.55

-0.72%↓

MDT

86.53

+0.49%↑

A

114.87

+1.31%↑

VEEV

173.27

-1.41%↓

HQY

81.97

+0.15%↑

CSBR

5.55

-0.72%↓

MDT

86.53

+0.49%↑

A

114.87

+1.31%↑

VEEV

173.27

-1.41%↓

HQY

81.97

+0.15%↑

CSBR

5.55

-0.72%↓

MDT

86.53

+0.49%↑

A

114.87

+1.31%↑

VEEV

173.27

-1.41%↓

HQY

81.97

+0.15%↑

CSBR

5.55

-0.72%↓

MDT

86.53

+0.49%↑

A

114.87

+1.31%↑

VEEV

173.27

-1.41%↓

HQY

81.97

+0.15%↑

CSBR

5.55

-0.72%↓

Search

CONMED Corp

Ouvert

SecteurSoins de santé

35.12 3.6

Résumé

Variation du prix de l'action

24h

Actuel

Min

33.93

Max

35.66

Chiffres clés

By Trading Economics

Revenu

14M

17M

Ventes

35M

373M

P/E

Moyenne du Secteur

24.258

57.05

BPA

1.43

Rendement du dividende

1.67

Marge bénéficiaire

4.485

Employés

3,900

EBITDA

25M

55M

Recommandations

By TipRanks

Recommandations

Neutre

Prévisions sur 12 Mois

+20.93% upside

Dividendes

By Dow Jones

Rendement du dividende

Moyenne du Secteur

1.67%

2.52%

Prochains Résultats

29 avr. 2026

Date du Prochain Dividende

3 avr. 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-135M

1.1B

Ouverture précédente

31.52

Clôture précédente

35.12

Sentiment de l'Actualité

By Acuity

17%

83%

32 / 349 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Very Strong Bullish Evidence

CONMED Corp Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

31 mars 2026, 23:31 UTC

Actions en Tendance

Stocks to Watch: Nike, RH, NCino

31 mars 2026, 22:35 UTC

Résultats

Nike Guides for Sales Declines Ahead as Turnaround Plan Hits Snags -- 2nd Update

1 avr. 2026, 00:00 UTC

Acquisitions, Fusions, Rachats

The Year Is Off to the Strongest Start for Big Deals Ever -- WSJ

31 mars 2026, 23:50 UTC

Acquisitions, Fusions, Rachats

Nxera Pharma: Partner Centessa Pharmaceuticals to Be Acquired by Lilly >LLY 4565.TO

31 mars 2026, 23:43 UTC

Market Talk

Nikkei May Rise on Hopes for Iran War Ending Soon -- Market Talk

31 mars 2026, 23:33 UTC

Market Talk
Principaux Événements d'Actualité

Gold Edges Higher on Signs of De-Escalating Middle East Tensions -- Market Talk

31 mars 2026, 23:21 UTC

Résultats

Nike Stock Slides on Tariff Impact Despite Earnings Beat; Turnaround Continues -- Barrons.com

31 mars 2026, 23:14 UTC

Market Talk
Résultats

Nike CEO Says Turnaround is Taking Longer Than He'd Like -- Market Talk

31 mars 2026, 23:12 UTC

Market Talk

Aurelia's Cash Flow Strength Highlighted by New Financing Deal -- Market Talk

31 mars 2026, 22:36 UTC

Résultats

China Vanke 2025 Loss Widens >000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke: Increase in Inventory Impariment Provision Among Factors Weighing On Results>000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke 2025 Loss CNY88.56B Vs. Loss CNY49.48B >000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke: Will Take Time to Resolve Issues Caused by High Debt Levels>000002.SZ

31 mars 2026, 22:36 UTC

Résultats

China Vanke 2025 Rev CNY233.43B Vs. CNY343.18B >000002.SZ

31 mars 2026, 21:46 UTC

Acquisitions, Fusions, Rachats

Big Drug Companies Hunting for Deals Are Lowering Their Sights -- WSJ

31 mars 2026, 21:36 UTC

Market Talk

West African Resources's Costs Higher Than Bull Expected -- Market Talk

31 mars 2026, 21:35 UTC

Résultats

Nike Expects China Sales Down 20% in 4Q, CFO Says

31 mars 2026, 21:35 UTC

Résultats

Nike Expects Modest Growth in North America, Offset by Declines in China, Converse Brand in 4Q, CFO Says

31 mars 2026, 21:35 UTC

Résultats

Nike Forecasts 4Q Sales Down 2% to 4%, CFO Says

31 mars 2026, 21:33 UTC

Acquisitions, Fusions, Rachats

Biotechs Are a Healthy Growth Bet Thanks to M&A and New Drugs -- Barrons.com

31 mars 2026, 21:33 UTC

Résultats

Nike Expects Sales Down Low-Single Digits From Now Through End of Calendar Year, CFO Says

31 mars 2026, 21:32 UTC

Résultats

Nike Expects 1Q to Be Final Quarter Where Tariffs Continue to Be Year-Over-Year Headwind to Margins, CFO Says

31 mars 2026, 21:28 UTC

Résultats

Nike Expects to End 4Q With Elevated Inventory, CFO Says

31 mars 2026, 21:26 UTC

Résultats

Nike Increasingly Confident It Will Return to Balanced Growth in North America in Direct, Wholesale Channels, CFO Says

31 mars 2026, 21:25 UTC

Résultats

Nike Expects Supply-Chain Changes to Pay Off Starting in Fiscal 2027, CFO Says

31 mars 2026, 21:24 UTC

Market Talk
Résultats

Nike: Turnaround Plan Progressing at Different Rates -- Market Talk

31 mars 2026, 21:22 UTC

Résultats

Nike CFO Expects Football Training and Basketball Will Return to Growth Over Next Few Quarters

31 mars 2026, 21:22 UTC

Résultats

Nike's Sportswear Business Declined Low-Double Digits in 3Q, CFO Says

31 mars 2026, 21:21 UTC

Résultats

Nike's Digital Channel Still Too Promotional, CFO Says

31 mars 2026, 21:20 UTC

Résultats

Nike CEO: Converse Remains Important to Portfolio

Comparaison

Variation de prix

CONMED Corp prévision

Objectif de Prix

By TipRanks

20.93% hausse

Prévisions sur 12 Mois

Moyen 40.5 USD  20.93%

Haut 42 USD

Bas 39 USD

Basé sur 3 analystes de Wall Street proposant des objectifs de prix à 12 mois pour Microsoft Corp. au cours des 3 derniers mois.

Note du Consensus

By TipRanks

Neutre

3 ratings

0

Achat

3

Maintien

0

Vente

Score Technique

By Trading Central

51 / 58.13Support & Résistance

Court Terme

Very Strong Bullish Evidence

Moyen Terme

Bullish Evidence

Long Terme

Strong Bearish Evidence

Sentiment

By Acuity

32 / 349Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos CONMED Corp

CONMED Corporation, a medical technology company, develops, manufactures, and sells surgical devices and related equipment for surgical procedures worldwide. The company offers orthopedic surgery products, including BioBrace, TruShot with Y-Knot All-In-One Soft Tissue Fixation System, Y-knot All-Suture Anchors, and Agro Knotless Suture Anchors, which provide clinical solutions to orthopedic surgeons for the augmentation and repair of soft tissue injuries, as well as provides supporting products that enable surgeons to perform minimally invasive sports medicine surgeries. It markets orthopedic surgery products under the Hall, CONMED Linvatec, Concept, and Shutt brands. The company also provides battery-powered and autoclavable bone power tool systems for use in orthopedic, arthroscopic, oral/maxillofacial, podiatric, spinal, and cardiothoracic surgeries under Hall surgical brand name. In addition, it offers general surgery products, including clinical insufflation systems under AirSeal brand; smoke removal devices under Buffalo Filter brand; endomechanical products, such as tissue retrieval bags, trocars, suction irrigation devices, graspers, scissors, and dissectors used in minimally invasive surgeries; and electrosurgical solution comprising monopolar and bipolar generators, argon beam coagulation generators, handpieces, smoke management systems and other accessories. Further, the company provides endoscopic technologies, including therapeutic and diagnostic products for use in gastroenterology procedures, and products for the treatment of diseases of the dilatation, hemostasis, biliary, structure management, and infection prevention and patient monitoring, including ECG and EEG electrodes, and cardiac defibrillation pads. It markets its products directly to hospitals, surgery centers, and other healthcare institutions, as well as through medical specialty distributors. CONMED Corporation was incorporated in 1970 and is headquartered in Largo, Florida.
help-icon Live chat